P3 Health Partners to issue up to $70 million in preferred stock and warrants to CPF
On September 8, 2026, P3 Health Partners entered a Securities Purchase Agreement with affiliates of CPF to issue up to $70 million of units in multiple tranches, each including Series D-1 19.5% Cumulative Preferred Stock and warrants. A special committee of independent directors approved the deal because the CPF affiliates may be related parties. The preferred stock ranks senior to common stock, and the warrants could add to the number of common shares outstanding.
Key points
- Up to $70 million of units to be issued in multiple tranches under a Securities Purchase Agreement dated September 8, 2026.
- Series D-1 preferred stock: 19.5% cumulative dividend, $100 stated value per share, not convertible, no voting rights, redeemable at $100 per share plus unpaid dividends.
- Warrants exercisable for 0.66333% of outstanding Class A and Class V common stock per $1,000,000 funded, with a seven-year term.
- CPF may designate one additional independent director while it owns 40% of common stock; the 49.99% standstill limit is extended from January 1, 2027 to December 31, 2027.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.